191 related articles for article (PubMed ID: 29134428)
1. The Influence of Hepatic and Renal Impairment on the Pharmacokinetics of a Treatment for Herpes Zoster, Amenamevir (ASP2151): Phase 1, Open-Label, Single-Dose, Parallel-Group Studies.
Kusawake T; Kowalski D; Takada A; Kato K; Katashima M; Keirns JJ; Lewand M; Lasseter KC; Marbury TC; Preston RA
Adv Ther; 2017 Dec; 34(12):2612-2624. PubMed ID: 29134428
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and Safety of Amenamevir in Healthy Subjects: Analysis of Four Randomized Phase 1 Studies.
Kusawake T; Keirns JJ; Kowalski D; den Adel M; Groenendaal-van de Meent D; Takada A; Ohtsu Y; Katashima M
Adv Ther; 2017 Dec; 34(12):2625-2637. PubMed ID: 29134426
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics and Dialyzability of a Single Oral Dose of Amenamevir, an Anti-Herpes Drug, in Hemodialysis Patients.
Tsuruoka S; Endo T; Seo M; Hashimoto N
Adv Ther; 2020 Jul; 37(7):3234-3245. PubMed ID: 32440976
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Kusawake T; den Adel M; Groenendaal-van de Meent D; Garcia-Hernandez A; Takada A; Kato K; Ohtsu Y; Katashima M
Adv Ther; 2017 Nov; 34(11):2466-2480. PubMed ID: 29076107
[TBL] [Abstract][Full Text] [Related]
5. Statistical analysis of Amenamevir (ASP2151) between pharmacokinetics and clinical efficacies with non-linear effect model for the treatment of genital herpes.
Takada A; Katashima M; Kaibara A; Sawamoto T; Zhang W; Keirns J
Clin Pharmacol Drug Dev; 2014 Sep; 3(5):365-70. PubMed ID: 27129009
[TBL] [Abstract][Full Text] [Related]
6. Amenamevir, a Helicase-Primase Inhibitor, for the Optimal Treatment of Herpes Zoster.
Shiraki K; Yasumoto S; Toyama N; Fukuda H
Viruses; 2021 Aug; 13(8):. PubMed ID: 34452412
[TBL] [Abstract][Full Text] [Related]
7. Helicase-primase inhibitor amenamevir for herpesvirus infection: Towards practical application for treating herpes zoster.
Shiraki K
Drugs Today (Barc); 2017 Nov; 53(11):573-584. PubMed ID: 29451274
[TBL] [Abstract][Full Text] [Related]
8. An Open-Label, Single-Dose, Human Mass Balance Study of Amenamevir in Healthy Male Adults.
Kato K; den Adel M; Groenendaal-van de Meent D; Ohtsu Y; Takada A; Katashima M
Clin Pharmacol Drug Dev; 2019 Jul; 8(5):595-602. PubMed ID: 30412362
[TBL] [Abstract][Full Text] [Related]
9. Amenamevir, a novel helicase-primase inhibitor, for treatment of herpes zoster: A randomized, double-blind, valaciclovir-controlled phase 3 study.
Kawashima M; Nemoto O; Honda M; Watanabe D; Nakayama J; Imafuku S; Kato T; Katsuramaki T;
J Dermatol; 2017 Nov; 44(11):1219-1227. PubMed ID: 28681394
[TBL] [Abstract][Full Text] [Related]
10. [Pharmacological profiles and clinical effects of amenamevir tablet as treatments for herpes zoster].
Maeda H; Nakamura H; Kikukawa Y
Nihon Yakurigaku Zasshi; 2019; 153(1):35-43. PubMed ID: 30643090
[TBL] [Abstract][Full Text] [Related]
11. Antiviral efficacy of the helicase-primase inhibitor amenamevir in murine models of severe herpesvirus infection.
Katsumata K; Chono K; Suzuki H
Biochem Pharmacol; 2018 Dec; 158():201-206. PubMed ID: 30365949
[TBL] [Abstract][Full Text] [Related]
12. Effect of hepatic or renal impairment on the pharmacokinetics of canagliflozin, a sodium glucose co-transporter 2 inhibitor.
Devineni D; Curtin CR; Marbury TC; Smith W; Vaccaro N; Wexler D; Vandebosch A; Rusch S; Stieltjes H; Wajs E
Clin Ther; 2015 Mar; 37(3):610-628.e4. PubMed ID: 25659911
[TBL] [Abstract][Full Text] [Related]
13. Pharmaceuticals and Medical Device Agency approval summary: Amenamevir for the treatment of herpes zoster.
Shoji N; Tanese K; Sasaki A; Horiuchi T; Utsuno Y; Fukuda K; Hoshino Y; Noda S; Minami H; Asakura W;
J Dermatol; 2020 Jul; 47(7):683-688. PubMed ID: 32424854
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics and Safety of DS-8500a, an Antidiabetic Drug, in Japanese Subjects with Hepatic or Renal Impairment: A Single-Center, Open-Label, Single-Dose Study.
Kato M; Ishizuka H; Taguchi T; Shiosakai K; Kamiyama E; Sata M; Yoshida T
Adv Ther; 2018 Aug; 35(8):1239-1250. PubMed ID: 29968010
[TBL] [Abstract][Full Text] [Related]
15. Absorption, Distribution, Metabolism, and Excretion of the Novel Helicase-Primase Inhibitor, Amenamevir (ASP2151), in Rodents.
Ohtsu Y; Susaki Y; Noguchi K
Eur J Drug Metab Pharmacokinet; 2018 Dec; 43(6):693-706. PubMed ID: 29748821
[TBL] [Abstract][Full Text] [Related]
16. [Varicella-zoster meningoencephalitis and vasculitis after treatment with amenamevir to herpes zoster in the trigeminal nerve area].
Taniguchi Y; Kano Y; Kitamura T; Miura T; Yamada K
Rinsho Shinkeigaku; 2021 Apr; 61(4):239-242. PubMed ID: 33762495
[TBL] [Abstract][Full Text] [Related]
17. Effect of renal impairment on the pharmacokinetics of intravenous zanamivir.
Cass LM; Efthymiopoulos C; Marsh J; Bye A
Clin Pharmacokinet; 1999; 36 Suppl 1():13-9. PubMed ID: 10429836
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of vandetanib in subjects with renal or hepatic impairment.
Weil A; Martin P; Smith R; Oliver S; Langmuir P; Read J; Molz KH
Clin Pharmacokinet; 2010 Sep; 49(9):607-18. PubMed ID: 20690783
[TBL] [Abstract][Full Text] [Related]
19. Amenamevir: Studies of Potential CYP3A-Mediated Pharmacokinetic Interactions With Midazolam, Cyclosporine, and Ritonavir in Healthy Volunteers.
Adeloye T; Sahgal O; Puri A; Warrington S; Endo T; Dennison J; Johnston A
Clin Pharmacol Drug Dev; 2018 Nov; 7(8):844-859. PubMed ID: 30044899
[TBL] [Abstract][Full Text] [Related]
20. ASP2151, a novel helicase-primase inhibitor, possesses antiviral activity against varicella-zoster virus and herpes simplex virus types 1 and 2.
Chono K; Katsumata K; Kontani T; Kobayashi M; Sudo K; Yokota T; Konno K; Shimizu Y; Suzuki H
J Antimicrob Chemother; 2010 Aug; 65(8):1733-41. PubMed ID: 20534624
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
